Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018 · View on ClinicalTrials.gov ↗
Study Summary
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Conditions Studied
Interventions
- BIOLOGICAL IgPro10
Study Locations (9)
Arizona
- Phoenix Children's Hospital — Phoenix
California
- Children's Hospital of Los Angeles — Los Angeles
Iowa
- University of Iowa Hospitals and Clinics — Iowa City
Ohio
- Akron Children's Hospital — Akron
Pennsylvania
- Children's Hospital of Philadelphia — Philadelphia
Tennessee
- Le Bonheur Children's Hospital — Memphis
Texas
- Neurology Rare Disease Center — Denton
Virginia
- Children's Specialty Group — Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-02-28 |
| Est. Completion | 2029-12-20 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03684018
The ClinicalTrials.gov registry entry for NCT03684018 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 85 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) appearing as the primary indexed condition, and to 1 intervention — of which IgPro10 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03684018 reports 9 study locations spanning 9 distinct geographic areas — top geographies include Arizona, California, Iowa. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03684018 about?
NCT03684018 is a clinical study titled "Two Dose Levels of Privigen in Pediatric CIDP". A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
What is the current status of trial NCT03684018?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2019-02-28. Estimated completion is 2029-12-20.
What conditions does trial NCT03684018 study?
This clinical trial studies the following conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03684018?
The interventions under investigation include: IgPro10 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03684018?
This trial is sponsored by CSL Behring, which has 85 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03684018 being conducted?
This trial has 9 study locations across Arizona, California, Iowa, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.